Integrated diagnostic solution for oesophageal cancer (DELTA)
Research type
Research Study
Full title
Integrated diagnostic solution for early detection of oesophageal cancer (DELTA)
IRAS ID
283505
Contact name
Rebecca Fitzgerald
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
3 years, 4 months, 1 days
Research summary
We have developed a non-endoscopic diagnostic test for Barrett's oEsophagus (BE) which involves a device called the Cytosponge combined with molecular biomarker Trefoil Factor 3 (TFF3) which has shown to be effective in increasing the detection of Barrett’s oesophagus in primary care (BEST3 study). The DELTA study is now needed to:
- Identify high risk patients in the primary care and secondary care setting
- Enabling diagnostic testing during the COVID situation since diagnostic endoscopy services are severely curtailed
- Build a transferable operating model for a nurse-led Cytosponge clinic
- Implement Artificial Intelligence algorithms for high throughput computational pathology for the Cytosponge-TFF3 test and endoscopic biopsies
- Undertake Health economicsand implementation research to assess effectiveness of the novel pathway including user preferences for patients and clinicians.REC name
East of England - Cambridge East Research Ethics Committee
REC reference
20/EE/0141
Date of REC Opinion
26 Jun 2020
REC opinion
Further Information Favourable Opinion